{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:38:37Z","timestamp":1790199517757,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.thromres.2015.09.007","type":"journal-article","created":{"date-parts":[[2015,9,13]],"date-time":"2015-09-13T02:08:20Z","timestamp":1442110100000},"page":"851-854","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring"],"prefix":"10.1016","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1915-3897","authenticated-orcid":false,"given":"P.M.","family":"Mannucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2015.09.007_bb0005","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2015.09.007_bb0010","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00134-014-3630-z","article-title":"Understanding organ dysfunction in thrombotic thrombocytopenic purpura","volume":"41","author":"Mannucci","year":"2015","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.thromres.2015.09.007_bb0015","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2015.09.007_bb0020","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic\u2013uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2015.09.007_bb0025","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2015.09.007_bb0030","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic\u2013uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2015.09.007_bb0035","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.thromres.2015.09.007_bb0040","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic\u2013uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2015.09.007_bb0045","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.229.229","article-title":"Caplacizumab, anti-VWF nanobody potentially changing the treatment paradigm in thrombotic thrombocytopenic purpura: results of the TITAN trial","author":"Peyvandi","year":"2014"},{"key":"10.1016\/j.thromres.2015.09.007_bb0050","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1111\/j.1537-2995.2009.02232.x","article-title":"Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura","volume":"49","author":"Knobl","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.thromres.2015.09.007_bb0055","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ajh.23106","article-title":"Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura","volume":"87","author":"Cataland","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2015.09.007_bb0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2141.2006.06264.x","article-title":"The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpura","volume":"135","author":"Scully","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2015.09.007_bb0065","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ajh.23527","article-title":"ADAMTS13 content in plasma-derived factor VIII\/von Willebrand factor concentrates","volume":"88","author":"Peyvandi","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2015.09.007_bb0070","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.thromres.2015.09.007_bb0075","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2012-01-403113","article-title":"Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura","volume":"120","author":"Lotta","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2015.09.007_bb0080","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2004-11-4490","article-title":"ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases","volume":"106","author":"Rieger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2015.09.007_bb0085","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura","volume":"124","author":"Hie","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2015.09.007_bb0090","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2003-01-0193","article-title":"ADAMTS13 activity in thrombotic thrombocytopenic purpura\u2013hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients","volume":"102","author":"Vesely","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2015.09.007_bb0095","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1182\/blood.V98.9.2730","article-title":"Changes in health and disease of the metalloprotease that cleaves von Willebrand factor","volume":"98","author":"Mannucci","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2015.09.007_bb0100","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/01.md.0000133622.03370.07","article-title":"Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement","volume":"83","author":"Coppo","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.thromres.2015.09.007_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.thromres.2015.09.007_bb0110","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/j.1537-2995.2010.02653.x","article-title":"The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange","volume":"50","author":"Bentley","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.thromres.2015.09.007_bb0115","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2141.2012.09032.x","article-title":"The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies","volume":"157","author":"Cataland","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2015.09.007_bb0120","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/blood-2013-11-516237","article-title":"How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2015.09.007_bb0125","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic\u2013uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.thromres.2015.09.007_bb0130","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.thromres.2015.09.007_bb0135","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.thromres.2015.09.007_bb0140","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","article-title":"Modified Ham test for atypical hemolytic uremic syndrome","volume":"125","author":"Gavriilaki","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2015.09.007_bb0145","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1182\/blood-2015-04-640656","article-title":"Atypical HUS, may become a diagnosis of inclusion","volume":"125","author":"Sadler","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2015.09.007_bb0150","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2013-12-547067","article-title":"Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2015.09.007_bb0155","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/cei.12426","article-title":"Complement activation patterns in atypical hemolytic uremic syndrome during acute phase and in remission","volume":"181","author":"Volokhina","year":"2015","journal-title":"Clin. Exp. Immunol"},{"key":"10.1016\/j.thromres.2015.09.007_bb0160","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2015.09.007_bb0165","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","article-title":"Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab","volume":"125","author":"Peffault de Latour","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2015.09.007_bb0170","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/jth.12764","article-title":"Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis: comment","volume":"13","author":"Cugno","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2015.09.007_bb0175","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jth.12615","article-title":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome","volume":"12","author":"Cugno","year":"2014","journal-title":"J. Thromb. Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384815301183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384815301183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T07:38:06Z","timestamp":1599550686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384815301183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0049384815301183"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2015.09.007","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2015.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}